bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

0.5271 UNCHANGED

Delayed Quote Updated: 11:33 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Warrant

< Previous 1 2 3 4 Next >

bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic

July 15, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging

July 09, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

June 26, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

June 24, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board

June 11, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 28, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung

June 03, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 20, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports First Quarter 2025 Results

May 15, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 07, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

May 06, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

April 17, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

March 31, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

March 26, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

March 19, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

March 13, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

March 06, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

February 26, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

February 25, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

January 22, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

January 13, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

December 17, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Set for Continued Expansion in 2025

December 12, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

December 05, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

November 14, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

November 04, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

October 30, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

October 21, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

October 18, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

August 23, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.